Incyte Corporation - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
INCY Nasdaq 2836 www.incyte.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Incyte Corporation

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia - Jun 13th, 2026 9:15 am
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival - Jun 13th, 2026 4:00 am
Incyte Buys Vega To Add Late Stage Von Willebrand Disease Opportunity - Jun 11th, 2026 9:12 pm
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings - Jun 11th, 2026 11:48 am
Why Incyte (INCY) Stock Is Up Today - Jun 10th, 2026 2:33 pm
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound? - Jun 10th, 2026 9:30 am
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges - Jun 10th, 2026 7:53 am
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B - Jun 9th, 2026 1:30 pm
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results - Jun 9th, 2026 7:29 am
Sector Update: Healthcare Stocks Decline Late Afternoon - Jun 8th, 2026 1:48 pm
Incyte To Acquire Vega Therapeutics For Up To $2 Billion - Jun 8th, 2026 7:52 am
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles - Jun 8th, 2026 5:16 am
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders - Jun 8th, 2026 5:00 am
Adma Biologics (ADMA) Down 5.8% Since Last Earnings Report: Can It Rebound? - Jun 5th, 2026 9:30 am
AbCellera Appoints Dr. Victor Sandor to its Board of Directors - Jun 5th, 2026 7:00 am
Is Tafasitamab’s First-Line DLBCL Win Reframing The Investment Case For Incyte (INCY)? - Jun 5th, 2026 6:06 am
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - Jun 4th, 2026 6:05 am
Centene, Deckers and 14 Other ‘Dividend Hopefuls’ - Jun 1st, 2026 11:30 pm
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL - May 30th, 2026 6:00 am
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report? - May 29th, 2026 9:30 am